^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF G469S

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1,
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over3years
    [VIRTUAL] Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial (ESMO 2021)
    Preliminary data confirmed the safety of B+E and demonstrated evidence of anti-tumor activity in advanced cancer pts with non-V600E BRAF mts. Enrolment in the BEAVER trial is ongoing.
    P2 data
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF D594G • BRAF D594N • BRAF G469S
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    over3years
    [VIRTUAL] Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts). (ASCO 2021)
    Preliminary data confirmed the safety of B+E and showed preliminary evidence of anti-tumor activity in advanced cancer pts with non-V600E BRAF mts . This study met the criterion for advancing to stage 2 . Enrolment in the BEAVER trial and correlative biomarker analyses are ongoing.
    P2 data
    |
    BRAF (B-raf proto-oncogene) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1)
    |
    BRAF V600E • BRAF D594N • BRAF G469S
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)